May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
6 citations
,
April 2016 in “Australasian journal of dermatology” Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
November 2024 in “Postępy Biochemii” Latanoprost may be a promising new treatment for hair loss.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
131 citations
,
October 2004 in “Clinical Cancer Research” Tempol is safe and may prevent hair loss from brain radiotherapy.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia” January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
2 citations
,
January 2021 in “Indian Journal of Dermatology, Venereology and Leprology” Betamethasone is more effective for hair regrowth than latanoprost but has more side effects.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
8 citations
,
January 2025 in “Gels” The developed nasal gel improves cilostazol delivery to the brain, enhancing its effectiveness and reducing side effects.
2 citations
,
February 2020 in “Rivista Urologia” Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.
9 citations
,
January 2024 in “International Journal of Dermatology”
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.